| Label item | Amount per 2-capsule serving | Notes |
|---|---|---|
| Palmitoylethanolamide (PEA) | 450 mg | Daily Value not established |
| Corydalis Powder (rhizome) | 150 mg | Daily Value not established |
| Gotu Kola Powder (whole herb) | 150 mg | Centella asiatica; Daily Value not established |
| Granular Alpha-Lipoic Acid (ALA) | 150 mg | Daily Value not established |
| Benfotiamine | 50 mg | Daily Value not established |
1. Palmitoylethanolamide (PEA) — 450 mg
PEA is a naturally occurring fatty-acid amide studied in inflammatory signaling and several pain-related clinical settings. A 2022 systematic review and meta-analysis reported favorable pooled findings but also emphasized very high study heterogeneity and signs of publication bias, meaning stronger randomized trials are still needed.
This ingredient evidence does not establish that a 450 mg serving within Nerve Armor will produce the same outcomes studied elsewhere.
2. Corydalis powder — 150 mg
Corydalis yanhusuo contains many alkaloids and has a long history of traditional use. Modern reviews describe pharmacological research on these alkaloids, but botanical identity, extraction, dose and preparation can vary substantially. The Nerve Armor label lists rhizome powder rather than a standardized alkaloid extract.
3. Gotu kola — 150 mg
Gotu kola (Centella asiatica) contains triterpenes that have been studied in neurological, skin and other research contexts. A review of the literature discusses anti-inflammatory and oxidative-stress pathways among several proposed mechanisms. Again, the Nerve Armor label lists whole-herb powder rather than a standardized research extract.
4. Alpha-lipoic acid — 150 mg
Alpha-lipoic acid is involved in cellular redox biology and has been studied in diabetic sensorimotor peripheral neuropathy. Trials and meta-analyses often use doses or clinical populations that do not match this product. Research in a diagnosed disease population should not be generalized into a treatment claim for an over-the-counter supplement.
5. Benfotiamine — 50 mg
Benfotiamine is a thiamine derivative. Older short-term trials suggested potential symptom benefits in diabetic polyneuropathy, while a 2026 randomized 12-month trial reported no significant effect across multiple morphometric, neurophysiological and clinical neuropathy outcomes. That more recent result is important context when describing the evidence.
Other ingredients
The supplied label lists HPMC (vegetable capsule), microcrystalline cellulose, magnesium stearate, olive oil and silicon dioxide.
What the formula does not prove by itself
A formula can contain ingredients with published research without the finished combination being clinically proven. Doses, combinations, bioavailability, participant populations and outcomes matter. This site therefore avoids phrases such as “clinically proven Nerve Armor” unless a finished-product trial can be verified.
References
- Scuteri et al. (2022) — PEA systematic review and meta-analysis
- Chen et al. (2022) — Analgesic properties of Corydalis yanhusuo
- Sun et al. (2020) — Centella asiatica and triterpenes review
- Han et al. (2023) — Oral alpha-lipoic acid meta-analysis
- Ziegler et al. (2026) — BOND randomized trial of benfotiamine
- NIH Office of Dietary Supplements — Thiamin Fact Sheet
Why the ingredient form matters as much as the ingredient name
Two labels can list the same common ingredient name while using materially different preparations. PEA may be micronized or non-micronized; botanical products may be whole herb, concentrated extract or standardized extract; alpha-lipoic acid can appear as different chemical forms; and thiamine derivatives are not interchangeable with ordinary food-source thiamine. Research interpretation therefore depends on more than matching a keyword.
The supplied Nerve Armor label is relatively specific for the botanicals: corydalis is listed as rhizome powder and gotu kola as whole-herb powder. That helps set a boundary when reading papers that use purified alkaloids or standardized triterpene extracts.
Combination formulas introduce an extra evidence question
Even if each ingredient has plausible research, combining them can change tolerability, adherence and total exposure. Researchers may study one compound under controlled conditions, while a consumer product provides five active ingredients at once. Without a trial of the finished combination, we can describe the formula and the separate literature but should not assume the mixture reproduces the best result reported for every component.
Why newer null findings matter
Supplement pages often cite older positive studies and stop there. The 2026 BOND benfotiamine trial is a useful counterexample: it found no significant improvement across multiple long-term neuropathy outcomes despite earlier short-term studies suggesting benefit. Scientific interpretation should change as stronger or longer studies become available.
Ingredient research is not a diagnosis tool
Learning that an ingredient has been studied in diabetic polyneuropathy does not mean a person with tingling has diabetic polyneuropathy, nor does it mean the ingredient is appropriate. Symptoms must be interpreted in the context of medical history, examination and, when necessary, testing.